Alpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, supply risk, customer concentration, and control weaknesses take over.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
